The case to infect volunteers with COVID-19 to accelerate vaccine testing | Nir Eyal

Episode Summary

Executive Summary: Bioethicist Nir Eyal argues for the ethical justification of human challenge trials to accelerate COVID-19 vaccine development. He posits that deliberately infecting young, healthy volunteers with the virus, after careful selection and informed consent, presents a tolerable risk level comparable to or lower than live kidney donation. Eyal contends that the potential to save thousands of lives by shortening the vaccine rollout time outweighs the risks, drawing parallels to accepted medical practices and the heroic volunteerism witnessed in the One Day Sooner initiative.

Main Topics: Ethical Justification for Challenge Trials (Priority: 5/5): Nir Eyal presents the core ethical argument for deliberately infecting volunteers with COVID-19 to test vaccine efficacy, comparing the risk to accepted practices like kidney donation and emphasizing the potential to save thousands of lives. Risk Assessment and Mitigation Strategies (Priority: 5/5): Discussion of methods to minimize risk in challenge trials, including selecting young participants (20s), excluding those with preconditions, and providing top-tier medical care. Eyal cites a baseline mortality risk of 1 in 12,000 for this group. Ethical Nuance: Action vs. Omission (Priority: 4/5): Exploration of the ethical distinction between actively putting volunteers at risk and passively allowing deaths from a delayed vaccine rollout, drawing parallels to the trolley car thought experiment. Marginalized Populations and Privilege (Priority: 4/5): Addressing the complex challenge of involving marginalized groups in trials to ensure vaccine efficacy across diverse populations, while avoiding exploitation and ensuring fully informed consent. Volunteer Motivation and Societal Recognition (Priority: 3/5): The role of altruistic volunteers (e.g., One Day Sooner) who are willing to accept risk for the greater good, and the idea that society should regard them as heroes comparable to astronauts or soldiers.

Key Arguments: Challenge trials can drastically shorten the time to determine vaccine efficacy, potentially saving thousands of lives dying daily from COVID-19. Through careful participant selection (young, healthy, likely to be exposed anyway), the net added risk to volunteers can be made lower than that of live kidney donation, a widely accepted practice. Informed consent from competent, understanding volunteers justifies the risk, especially when the potential benefit is saving many lives. The ethical calculus of action versus omission suggests that failing to accelerate vaccine development via challenge trials may cause more harm than conducting them. Providing the best medical care and involving volunteers as partners in planning further mitigates ethical concerns.

Data Points: Daily COVID-19 deaths at time of talk: 4,000-5,000 - Context for the urgency of accelerating vaccine development. Mortality risk for participants in optimal challenge trial: 1 in 12,000 - Baseline risk for young people (20s) in general population; risk would be further reduced by excluding preconditions. Mortality risk from live kidney donation: 1 in 3,000 - Used as a benchmark for an accepted medical risk that is higher than the proposed challenge trial risk. Potential number of lives saved by shortening vaccine rollout by one month: 150,000 - Rough estimate based on daily death numbers.

Pivotal Quotes: "Once you do those things, you get to a level of risk that is far lower than that of kidney donation. In kidney donation, we allow it because it's good for one other person... The difference is that in this case, we're talking about not just one person aided by this, but potentially many thousand saved from death or for impoverishment." — Nir Eyal: Eyal summarizing the ethical balance that supports challenge trials, comparing the risk to kidney donation. "In this particular case, I would kind of cut the chase and say: look, look at the analogy of organ transplantation. Look also the analogy of medical trials that do something very similar. They put healthy people at risk so we can develop drugs and vaccines." — Nir Eyal: Eyal responding to the trolley car problem analogy, arguing that consent and known risk levels differentiate challenge trials from the classic ethical dilemma. "I'm actually in touch with these people, and they are... I'm floored by their courage, by the intelligence... Many of them are graduates of the best universities in the world or teachers in the best universities in the world. And an amazing combination of courage, intelligence, good intentions..." — Nir Eyal: Eyal describing the volunteers from One Day Sooner, framing them as heroic and capable of giving fully informed consent.

Implications: This conversation frames challenge trials not as a reckless gamble, but as a potentially ethical, risk-managed strategy to save lives. It challenges the public and regulators to reconsider risk tolerance in the face of a pandemic, emphasizing that cautious inaction has a deadly cost. The dialogue could influence vaccine trial policies and public perception of volunteerism in medical research.